Suppr超能文献

活化型Akt在良性痣、Spitz痣和黑色素瘤中的表达。

Expression of activated Akt in benign nevi, Spitz nevi and melanomas.

作者信息

Kantrow Sara M, Boyd Alan S, Ellis Darrel L, Nanney Lillian B, Richmond Ann, Shyr Yu, Robbins Jason B

机构信息

Department of Medicine (Dermatology), Vanderbilt University Nashville, TN, USA.

出版信息

J Cutan Pathol. 2007 Aug;34(8):593-6. doi: 10.1111/j.1600-0560.2006.00675.x.

Abstract

BACKGROUND

Activated Akt expression (p-Akt) is reportedly increased in many melanomas as compared with benign nevi. The purpose of this study was to evaluate and compare p-Akt immunohistological staining in benign nevi, Spitz nevi and primary melanomas.

METHODS

Immunostaining for phosphorylated Akt was performed in 41 melanocytic lesions previously classified as benign intradermal nevus (14 lesions), Spitz nevus (9 lesions) or melanoma (18 lesions). Lesions were graded for intensity of p-Akt staining by two independent observers (0, no staining; 1, slightly positive; 2, moderately positive; 3, highly positive). Scores were averaged, and statistical analyses were performed.

RESULTS

Benign nevi showed less staining (mean score 1.18) compared with Spitz nevi (mean score 2.11) and melanomas (mean score 2.19). This difference was statistically significant between benign nevi and melanomas (p = 0.0047) and benign nevi and Spitz nevi (p = 0.0271). No statistical difference was detected in staining between Spitz nevi and melanomas (p = 0.8309).

CONCLUSIONS

Activated Akt expression is increased in Spitz nevi and melanomas as compared with benign intradermal nevi, but is unlikely to prove useful in differentiating between the former.

摘要

背景

据报道,与良性痣相比,许多黑色素瘤中活化的Akt表达(p-Akt)增加。本研究的目的是评估和比较良性痣、Spitz痣和原发性黑色素瘤中p-Akt的免疫组织化学染色。

方法

对41个先前分类为良性真皮内痣(14个病变)、Spitz痣(9个病变)或黑色素瘤(18个病变)的黑素细胞病变进行磷酸化Akt的免疫染色。由两名独立观察者对病变的p-Akt染色强度进行分级(0,无染色;1,弱阳性;2,中度阳性;3,强阳性)。对分数进行平均,并进行统计分析。

结果

与Spitz痣(平均分数2.11)和黑色素瘤(平均分数2.19)相比,良性痣的染色较少(平均分数1.18)。良性痣与黑色素瘤之间(p = 0.0047)以及良性痣与Spitz痣之间(p = 0.0271)的这种差异具有统计学意义。Spitz痣和黑色素瘤之间的染色未检测到统计学差异(p = 0.8309)。

结论

与良性真皮内痣相比,Spitz痣和黑色素瘤中活化的Akt表达增加,但不太可能有助于区分两者。

相似文献

1
Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
J Cutan Pathol. 2007 Aug;34(8):593-6. doi: 10.1111/j.1600-0560.2006.00675.x.
2
Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
J Cutan Pathol. 2006 Jan;33(1):33-7. doi: 10.1111/j.0303-6987.2006.00420.x.
3
Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
Am J Dermatopathol. 1999 Apr;21(2):115-20. doi: 10.1097/00000372-199904000-00001.
4
Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.
Mod Pathol. 2005 Feb;18(2):197-204. doi: 10.1038/modpathol.3800281.
5
Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
J Cutan Pathol. 2009 Apr;36(4):433-8. doi: 10.1111/j.1600-0560.2008.01077.x.
6
BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Hum Pathol. 2015 Feb;46(2):239-45. doi: 10.1016/j.humpath.2014.10.015. Epub 2014 Nov 4.
7
p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
J Am Acad Dermatol. 2011 Aug;65(2):357-363. doi: 10.1016/j.jaad.2010.07.031. Epub 2011 May 6.
8
S100A6 protein expression is different in Spitz nevi and melanomas.
Mod Pathol. 2003 May;16(5):505-11. doi: 10.1097/01.MP.0000071128.67149.FD.
9
Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
J Cutan Pathol. 2019 May;46(5):310-316. doi: 10.1111/cup.13424. Epub 2019 Feb 14.
10
The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Eur J Histochem. 2011 Jun 7;55(2):e20. doi: 10.4081/ejh.2011.e20.

引用本文的文献

1
Melanocytic nevi and melanoma: unraveling a complex relationship.
Oncogene. 2017 Oct 19;36(42):5771-5792. doi: 10.1038/onc.2017.189. Epub 2017 Jun 12.
2
Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.
Int J Clin Exp Pathol. 2015 Sep 1;8(9):9742-51. eCollection 2015.
3
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
Cancer Cell. 2015 Jan 12;27(1):41-56. doi: 10.1016/j.ccell.2014.11.014.
4
Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
Clin Cancer Res. 2013 Oct 1;19(19):5310-9. doi: 10.1158/1078-0432.CCR-13-0142.
7
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867.
8
Understanding signaling cascades in melanoma.
Photochem Photobiol. 2008 Mar-Apr;84(2):289-306. doi: 10.1111/j.1751-1097.2007.00254.x. Epub 2007 Dec 15.

本文引用的文献

1
The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment.
Mod Pathol. 2006 Feb;19 Suppl 2:S21-33. doi: 10.1038/modpathol.3800519.
2
Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
J Cutan Pathol. 2006 Jan;33(1):33-7. doi: 10.1111/j.0303-6987.2006.00420.x.
3
hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
J Cutan Pathol. 2005 Nov;32(10):680-4. doi: 10.1111/j.0303-6987.2005.00403.x.
4
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
Am J Clin Pathol. 2005 Oct;124(4):528-36. doi: 10.1309/YT58WWMTA6YR1PRV.
5
Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions.
Arch Dermatol Res. 2005 Jul;297(1):26-30. doi: 10.1007/s00403-005-0572-x. Epub 2005 May 19.
6
7
Deregulated Akt3 activity promotes development of malignant melanoma.
Cancer Res. 2004 Oct 1;64(19):7002-10. doi: 10.1158/0008-5472.CAN-04-1399.
8
PI3K/Akt signalling pathway and cancer.
Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007.
9
Apoptosis and melanoma chemoresistance.
Oncogene. 2003 May 19;22(20):3138-51. doi: 10.1038/sj.onc.1206454.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验